DK1465995T3 - Bispespecifikke antisense-olignukleotider der inhiberer IGFBP-2 og IGFBP og fremgangsmåder til anvendelse deraf - Google Patents

Bispespecifikke antisense-olignukleotider der inhiberer IGFBP-2 og IGFBP og fremgangsmåder til anvendelse deraf

Info

Publication number
DK1465995T3
DK1465995T3 DK03731644T DK03731644T DK1465995T3 DK 1465995 T3 DK1465995 T3 DK 1465995T3 DK 03731644 T DK03731644 T DK 03731644T DK 03731644 T DK03731644 T DK 03731644T DK 1465995 T3 DK1465995 T3 DK 1465995T3
Authority
DK
Denmark
Prior art keywords
igfbp
antisense oligonucleotides
methods
bispecific antisense
oligonucleotides inhibiting
Prior art date
Application number
DK03731644T
Other languages
Danish (da)
English (en)
Inventor
Martin Gleave
Maxim Signaevsky
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of DK1465995T3 publication Critical patent/DK1465995T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03731644T 2002-01-17 2003-01-17 Bispespecifikke antisense-olignukleotider der inhiberer IGFBP-2 og IGFBP og fremgangsmåder til anvendelse deraf DK1465995T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35004602P 2002-01-17 2002-01-17
PCT/CA2003/000061 WO2003062421A1 (fr) 2002-01-17 2003-01-17 Oligonucleotides antisens bispecifiques qui inhibent l'igfbp-2 et l'igfbp-5 et procedes d'utilisation associes

Publications (1)

Publication Number Publication Date
DK1465995T3 true DK1465995T3 (da) 2008-10-20

Family

ID=27613360

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03731644T DK1465995T3 (da) 2002-01-17 2003-01-17 Bispespecifikke antisense-olignukleotider der inhiberer IGFBP-2 og IGFBP og fremgangsmåder til anvendelse deraf

Country Status (15)

Country Link
US (11) US20030158143A1 (fr)
EP (1) EP1465995B1 (fr)
JP (1) JP4491240B2 (fr)
KR (2) KR101166214B1 (fr)
AT (1) ATE402999T1 (fr)
AU (1) AU2003237616B2 (fr)
CA (1) CA2469685C (fr)
DE (1) DE60322509D1 (fr)
DK (1) DK1465995T3 (fr)
ES (1) ES2307942T3 (fr)
HU (1) HU229452B1 (fr)
IL (2) IL162540A0 (fr)
NO (1) NO333017B1 (fr)
NZ (1) NZ533126A (fr)
WO (1) WO2003062421A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850318A1 (fr) 1999-02-26 2000-08-31 The University Of British Columbia Therapie anti-sens a message de regression prostatique par la testosterone (trpm-2)
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
HU229452B1 (en) * 2002-01-17 2013-12-30 Univ British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
KR101117673B1 (ko) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
DK1530636T3 (da) * 2002-08-21 2010-11-29 Univ British Columbia Behandling af melanomer ved reduktion af clusterinniveauet
EP1560933A4 (fr) * 2002-11-14 2007-11-21 Wyeth Corp Methodes et compositions permettant de traiter des troubles neurologiques
EP1667731B1 (fr) * 2003-10-01 2013-05-22 The University Of British Columbia Oligonucleotide bispecifique pour le traitement des malignites du systeme nerveux central
WO2005094899A1 (fr) 2004-04-02 2005-10-13 The University Of British Columbia Traitement de cancers par un antisens anti-clusterine
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
AU2005309274B2 (en) * 2004-11-23 2011-07-21 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the EGF signaling pathway and an oligonucleotide that reduces clusterin levels
US7315916B2 (en) * 2004-12-16 2008-01-01 Sandisk Corporation Scratch pad block
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
EP2087152B1 (fr) * 2006-10-27 2015-03-11 Walfish, Paul Biomarqueurs endométriaux
ES2734886T3 (es) 2009-11-24 2019-12-12 Alethia Biotherapeutics Inc Anticuerpos anti-clusterina y fragmentos de unión a antígeno y su uso para reducir el volumen tumoral
WO2011109262A2 (fr) 2010-03-01 2011-09-09 Tau Therapeutics Llc Diagnostic du cancer et imagerie
CN103958681A (zh) * 2011-05-19 2014-07-30 泰华制药工业有限公司 治疗非小细胞肺癌的方法
SG11201400526TA (en) 2011-09-12 2014-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
CN104159611A (zh) 2012-02-22 2014-11-19 阿莱斯亚生物疗法股份有限公司 共使用簇集蛋白抑制剂和egfr抑制剂以治疗癌症
CA2844640A1 (fr) * 2013-12-06 2015-06-06 The University Of British Columbia Procede de traitement du cancer de la prostate resistant a la castration
SG10202104058XA (en) * 2015-10-14 2021-05-28 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
AU2016341429B2 (en) 2015-10-22 2023-09-21 Cavion, Inc. Methods for treating Angelman Syndrome and related disorders
US10496215B2 (en) * 2016-04-29 2019-12-03 Synaptics Incorporated Sensing for touch and force
ES2928654T3 (es) 2016-09-16 2022-11-21 Bio Path Holdings Inc Terapia combinada con oligonucleótidos antisentido liposomales
AU2018221722B2 (en) 2017-02-15 2022-02-03 Cavion, Inc. Calcium channel inhibitors
US11041153B2 (en) 2017-04-19 2021-06-22 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for STAT3 inhibition
JP7321097B2 (ja) 2017-04-26 2023-08-04 カビオン・インコーポレイテッド 記憶および認知を改善する、ならびに記憶および認知障害を処置するための方法
KR102068302B1 (ko) 2018-07-25 2020-01-20 정준모 봉투 고정장치
CA3115235A1 (fr) 2018-10-03 2020-04-09 Cavion, Inc. Traitement des tremblements essentiels a l'aide de (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98805B (pt) 1990-08-28 1999-01-29 Chiron Corp Processo de preparacao de uma nova proteina de ligacao ao factor de crescimento semelhante a insulina (igfbp-4)
PT98806B (pt) 1990-08-28 1999-01-29 Chiron Corp Processo de preparacao de uma molecula de dna, um microorganismo ou linha celular recombinantes, e de producao da igfbp-4 ou um seu fragmento
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
AU1313095A (en) 1993-12-23 1995-07-10 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
SK109198A3 (en) 1996-02-14 1999-06-11 Isis Pharmaceuticals Inc Sugar-modified gapped oligonucleotides
US5910583A (en) 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6335194B1 (en) 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
EE200100271A (et) 1998-11-19 2002-10-15 Warner-Lambert Company N-[4-(3-kloro-4-fluorofenüülamino)-7-(3-morfoliin-4-üülpropoksü)kinasoliin-6-üül]ak rüülamiid kui türosiinkinaaside pöördumatu inhibiitor
US6464975B2 (en) 1998-12-11 2002-10-15 The Research Foundation Of State University Of New York Compositions and methods for altering cell migration
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
CA2850318A1 (fr) 1999-02-26 2000-08-31 The University Of British Columbia Therapie anti-sens a message de regression prostatique par la testosterone (trpm-2)
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2000069454A1 (fr) 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression de l'igfbp-2 endogene visant a inhiber le cancer
WO2000078341A1 (fr) * 1999-06-21 2000-12-28 Murdoch Childrens Research Institute Methode de prophylaxie et/ou de traitement de troubles cliniques
CA2373721C (fr) 1999-07-02 2013-10-15 Genentech, Inc. Composes se liant a her2
AU772480B2 (en) * 1999-07-19 2004-04-29 University Of British Columbia, The Antisense therapy for hormone-regulated tumors
US6310047B1 (en) * 1999-08-24 2001-10-30 Virginia Commonwealth University High affinity DNA binding compounds as adjuvants in antisense technology
EP1242050A4 (fr) 1999-12-21 2004-05-26 Univ Yale Stimulation de l'angiogen se par l'utilisation de survivine
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
AU9092001A (en) * 2000-09-14 2002-03-26 Univ British Columbia Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
WO2002044321A2 (fr) * 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Petites molecules d'arn mediant l'interference arn
WO2002097114A2 (fr) 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Traitement a l'acide nucleique de maladies ou d'affections associees aux taux de ras, her2 et hiv
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
DE10152005A1 (de) 2001-10-22 2003-04-30 Bayer Cropscience Ag Pyrazolylsubstituierte Heterocyclen
US20050123896A1 (en) 2001-10-25 2005-06-09 Benz Christopher C. Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
HU229452B1 (en) * 2002-01-17 2013-12-30 Univ British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
WO2003097855A2 (fr) 2002-05-14 2003-11-27 Baylor College Of Medicine Petites molecules inhibitrices de l'expression du gene her2
KR101117673B1 (ko) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
DK1530636T3 (da) 2002-08-21 2010-11-29 Univ British Columbia Behandling af melanomer ved reduktion af clusterinniveauet
US20040220131A1 (en) 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
EP1667731B1 (fr) * 2003-10-01 2013-05-22 The University Of British Columbia Oligonucleotide bispecifique pour le traitement des malignites du systeme nerveux central
AU2010277554B2 (en) * 2009-07-30 2015-02-19 Antisense Pharma Gmbh Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system

Also Published As

Publication number Publication date
HUP0402543A2 (hu) 2005-03-29
US8835401B2 (en) 2014-09-16
HUP0402543A3 (en) 2012-09-28
NO20043401L (no) 2004-10-13
US20110196019A1 (en) 2011-08-11
US20160002630A1 (en) 2016-01-07
CA2469685C (fr) 2013-03-12
DE60322509D1 (de) 2008-09-11
US20100267808A1 (en) 2010-10-21
US20110190382A1 (en) 2011-08-04
US20130096180A1 (en) 2013-04-18
US9101646B2 (en) 2015-08-11
US8580761B2 (en) 2013-11-12
HU229452B1 (en) 2013-12-30
US20030158143A1 (en) 2003-08-21
US7973017B2 (en) 2011-07-05
US20120220646A1 (en) 2012-08-30
NO333017B1 (no) 2013-02-18
US8470796B2 (en) 2013-06-25
US20130303592A1 (en) 2013-11-14
US20060122141A1 (en) 2006-06-08
EP1465995B1 (fr) 2008-07-30
US8541390B2 (en) 2013-09-24
ES2307942T3 (es) 2008-12-01
JP4491240B2 (ja) 2010-06-30
AU2003237616B2 (en) 2007-07-05
ATE402999T1 (de) 2008-08-15
KR20110026023A (ko) 2011-03-14
KR101265180B1 (ko) 2013-05-29
NZ533126A (en) 2006-04-28
US8252765B2 (en) 2012-08-28
US7928082B2 (en) 2011-04-19
KR20040085150A (ko) 2004-10-07
IL162540A0 (en) 2005-11-20
WO2003062421A1 (fr) 2003-07-31
EP1465995A1 (fr) 2004-10-13
IL162540A (en) 2011-06-30
KR101166214B1 (ko) 2012-07-16
CA2469685A1 (fr) 2003-07-31
US8389491B2 (en) 2013-03-05
JP2005514948A (ja) 2005-05-26
US20120077861A1 (en) 2012-03-29
US20080261912A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
DK1465995T3 (da) Bispespecifikke antisense-olignukleotider der inhiberer IGFBP-2 og IGFBP og fremgangsmåder til anvendelse deraf
HK1095749A1 (en) Novel use of peptide compounds for in production of pharmacenticals for treating central neuropathic pain
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
ATE471717T1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
HUP0402162A2 (hu) A humán angiopoietin-2 specifikus kötőanyagai
CY1106991T1 (el) Αντιπολλαπλασιαστικη δραση ολιγονουκλεοτιδιων πλουσιων σε g και μεθοδος χρησιμοποιησης αυτων για την προσδεση σε νουκλεολινη
HUP0301179A2 (hu) Módosított VIII-as faktor
DE60325967D1 (de) Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen
AU2003243059A8 (en) Use of repression blocking sequences in methods for enhancing gene expression
EP1546285A4 (fr) Traitement inhibiteur de nitrification des sols de paturage
TW200628168A (en) Use of organic compounds
DE602004022935D1 (de) Verbesserungen des stimulationserfolgs-managements
IL149416A0 (en) Human enzymes of the metalloprotease family
EP1827458A4 (fr) Inhibition selective de rock 1 dans une therapie cardiaque
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
AU2003206945A8 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
ATE442382T1 (de) Ein die mam-domäne enthaltendes protein
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
PT1163333E (pt) ''inibidores da síntese de endotelina-1''
UA87117C2 (ru) Применение пептидных соединений для лечения центральной невропатической боли
MXPA05008817A (es) Derivados de esteres lipidos de nucleotidos.
IL169256A0 (en) Metalloprotease proteins
EP1567160A4 (fr) Procede de traitement de l'infarctus du myocarde
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen